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FcεRI-evoked allergic responses are initiated 
by mast cells through releasing granules con-
taining histamine, β-hexosaminidase, and mast 
cell–specifi  c proteases and by secreting infl  am-
matory cytokines (1). As a member of the  immune 
receptor superfamily, the FcεRI is composed 
of IgE-binding α subunit and signal- transducing 
β and γ subunits (2). Upon cross-linking of the 
FcεRI, the Src family protein tyrosine kinase 
Lyn is activated and phosphorylates the immuno-
receptor tyrosine-based activation motifs in the 
cytoplasmic domains of the β and γ subunits 
leading to recruitment of Syk. Syk is then 
a  ctivated and further phosphorylates linker for 
  activation of T cells (LAT), SLP-76, and several 
other signaling molecules (3).
Upon phosphorylation, LAT assembles a 
complex of signaling proteins containing Grb2, 
Gads, SLP-76, and phospholipase C (PLC)γ1/γ2 
(4, 5). Recruitment of Sos to LAT by Grb2 
likely leads to activation of the Ras–mitogen-
activated protein kinase (MAPK) pathway. 
Binding of PLCγ to LAT is necessary for acti-
vation of PLCγ. PLCγ catalyzes the generation 
of inositol 1,4,5-triphosphate and diacylglycerol 
(DAG), which are responsible for inducing 
calcium infl  ux and protein kinase C (PKC) 
activation, respectively. In the absence of LAT, 
signaling pathways downstream of the FcεRI 
are impaired. The phosphorylation of SLP-76 
and PLCγ1/γ2 as well as calcium fl  ux are sig-
nifi  cantly reduced. Consequently, mast cell de-
granulation and cytokine production are severely 
aff  ected in LAT−/− mast cells (4).
After FcεRI aggregation, another Src fam-
ily kinase, Fyn, is also activated and phosphory-
lates Gab2. After phosphorylation, Gab2 binds 
the p85 subunit of phosphatidyl inositol 3 ki-
nase (PI3K). Studies using Gab2−/− mast cells 
show that Gab2 is essential for PI3K activation 
(6, 7). However, it is not clear how PI3K is 
  activated after recruitment to the plasma mem-
brane by Gab2. Previous data show that in 
platelet-  derived growth factor receptor–mediated 
signaling, GTP-bound Ras is capable of acti-
vating PI3K by binding to the p110 catalytic 
subunit (8). After PI3K activation, phosphatidyl 
inositol-3,4,5-triphosphate (PIP3)-dependent 
kinase 1 (PDK1) is relocated to the membrane 
by binding to PIP3 and activated through in-
termolecular auto-phosphorylation (9). PDK1 
then phosphorylates and activates Akt and 
PKCδ. Fyn-defi  cient mast cells have impaired 
PI3K activation and degranulation (6), indicat-
ing that the Fyn-initiated pathway is important 
in mast cell degranulation. Recent studies 
show that cytoskeleton rearrangement, which 
is regulated by the PI3K pathway, is required 
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for granule translocation and mast cell degranulation (10–12). 
It has been suggested that degranulation is a two-step 
process: granule translocation to the plasma membrane 
and granule–plasma membrane fusion. Although granule 
translocation requires Fyn/Gab2, RhoA, and microtubule 
formation, granule–plasma membrane fusion is calcium 
  dependent (10).
Ras guanyl nucleotide-releasing proteins (RasGRPs) are 
a family of proteins that contain a DAG-binding C1 domain, 
a Ras exchange motif domain, two EF-hands, and a guanine-
nucleotide exchange factor (GEF) domain (13). After PLCγ 
activation, RasGRPs are recruited to the plasma membrane 
by binding to DAG for subsequent activation of Ras family 
proteins. Among the four RasGRP proteins, RasGRP1 has 
been shown to play an important role in TCR signaling and 
T cell development. T cell development is partially blocked 
at the double-positive stage in RasGRP1−/− mice (14). Thy-
mocytes from these mice show a complete lack of Erk ac-
tivation in response to PMA, a DAG analogue, or TCR 
cross-linking, demonstrating that RasGRP1 links the TCR 
to Ras signaling. It has been suggested that RasGRP1 inter-
acts with and activates Ras in the Golgi instead of the plasma 
membrane (15). RasGRP2 is a candidate oncogene causing 
leukemia and regulates platelet activation (16, 17). RasGRP3 
is preferentially expressed in B cells. It is phosphorylated after 
BCR stimulation (18). It has been demonstrated in the DT40 
cell line that RasGRP3 is required for optimal activation of 
Erk upon BCR cross-linking (19). RasGRP4 is a new member 
of the RasGRP family. It is highly expressed in myeloid 
cells, including mast cells (20, 21). It is not known whether 
  RasGRP4 functions in mast cells.
Despite the fact that RasGRP1 plays an essential role in 
TCR-mediated Ras-MAPK activation, whether it functions 
in FcεRI-mediated signaling in mast cells has not been 
explored. In this study, we demonstrate that RasGRP1 plays 
an important role in FcεRI-mediated PI3K activation and 
mast cell function.
RESULTS
Expression of RasGRP1 in mast cells
To assess the potential function of RasGRP1 in mast cells 
and allergic responses, we fi  rst examined whether RasGRP1 
is expressed in mast cells. Bone marrow–derived mast cells 
(BMMCs) were derived from the bone marrow cells from 
WT and RasGRP1−/− mice. After growing in medium with 
IL-3 for 3 wk, >99% of cultured cells were c-Kit+ and 
FcεRI+. RasGRP1−/− cells expressed similar levels of c-Kit 
and FcεRI as WT cells (Fig. 1 A), suggesting that RasGRP1 
is dispensable for mast cell diff   erentiation and maturation 
in vitro. These mast cells were used for detection of 
RasGRP1 protein and subsequent biochemical and functional 
assays. To detect RasGRP1 expression, lysates of WT and 
RasGRP1−/− mast cells were subjected to anti-RasGRP1 
immunoprecipitation. Lysates from WT and RasGRP1−/− 
thymocytes were used as controls. The total lysates and 
  immunoprecipitates were analyzed by an anti-RasGRP1 
Figure 1.  RasGRP1 in Fc𝗆RI-mediated degranulation. (A) Expression 
of c-Kit and FcεRI in WT and RasGRP1−/− BMMCs. (B) Expression of 
  RasGRP1 and RasGRP4 in mast cells. Mast cell lysates were analyzed by 
Western blotting with anti-RasGRP1, RasGRP4, Erk2, or HSP70 antibodies 
or immunoprecipitated with anti-RasGRP1 antibodies. The numbers 
shown are relative quantifi  cation of RasGRP1 in thymocytes and BMMCs. 
(C) Effect of RasGRP1 inactivation on FcεRI-mediated degranulation. 
BMMCs were sensitized with anti-DNP IgE and then stimulated with vari-
ous concentrations of DNP-HSA for 10 min. Degranulation data were 
expressed as percentages of the released verses total β-hexosaminidase 
activity and refl  ect three independent experiments. (D) Thapsigargin-
induced degranulation.JEM VOL. 204, January 22, 2007  95
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Western blot. As shown in Fig. 1 B, RasGRP1 protein was 
clearly detected in WT BMMCs, although not as abundant 
as in thymocytes. We also examined the expression of 
RasGRP4 by Western blotting with anti-RasGRP4 antibodies. 
As reported previously (20, 21), mast cells expressed high 
amounts of RasGRP4, which was not detected in thymo-
cytes (Fig. 1 B).
RasGRP1 is required for mast cell degranulation
Next, we investigated whether RasGRP1 functions in 
FcεRI-evoked degranulation. BMMCs were sensitized with 
anti-DNP IgE and stimulated with DNP-HSA at 1, 10, 100, 
and 1,000 ng/ml to induce degranulation, which was deter-
mined by measuring the release of β-hexosaminidase. As 
shown in Fig. 1 C, FcεRI-evoked degranulation was mark-
edly impaired in RasGRP1−/− BMMCs. This defect was not 
due to their inability to degranulate because thapsigargin, 
a calcium ATPase inhibitor, was capable of inducing 
RasGRP1−/− BMMCs to degranulate (Fig. 1 D). To deter-
mine whether granule formation was normal in RasGRP1−/− 
mast cells, we stained mast cells with toluidine blue. Similar 
granules were seen in WT and RasGRP1−/− cells (not 
  depicted). Thus, defective signaling after FcεRI engagement 
likely caused the diminished degranulation.
Impaired cytokine production in RasGRP1−/− BMMCs
Upon FcεRI cross-linking, mast cells secrete cytokines, such 
as IL-6, TNFα, IL-3, and IL-4. These cytokines play an 
important role in the allergic response (22). Next, we exam-
ined FcεRI-mediated cytokine production by RasGRP1−/− 
BMMCs. Total RNAs were prepared from mast cells acti-
vated for 1 h and were used in RT-PCR. Amplifi  cation of 
the  β-actin transcript indicated that similar amounts of 
  cDNAs were used (Fig. 2 A). Although IL-6 RNA synthesis was 
reduced slightly, transcription of TNFα, IL-4, and IL-3 was 
signifi  cantly decreased in RasGRP1−/− BMMCs (Fig. 2 A). 
These results were further confi  rmed by quantitation of cyto-
kines secreted into the culture medium at 8 h after stimulation. 
Although IL-6 production was relatively normal, secretion of 
TNFα, IL-3, and IL-4 by RasGRP1−/− cells after stimula-
tion was signifi  cantly reduced (Fig. 2 B). These results indi-
cated that RasGRP1 is required for cytokine production 
upon FcεRI engagement.
Severely defective systemic anaphylaxis in RasGRP1−/− mice
To investigate the impact of RasGRP1 inactivation on al-
lergic response in vivo, we performed IgE-evoked systemic 
anaphylaxis on WT and RasGRP1−/− mice. Anti-DNP IgE 
was intravenously injected into mice 24 h before challenge 
Figure 2.  Effect of RasGRP1 defi  ciency on cytokine release and 
passive systemic anaphylaxis. (A) FcεRI-induced cytokine RNA synthesis 
in WT and RasGRP1−/− BMMCs. Sensitized BMMCs were stimulated with 
30 ng/ml DNP-HSA for 1 h or left unstimulated before RNA preparation. 
cDNAs were serially diluted and used in RT-PCR. Data shown are repre-
sentative of two independent experiments with similar results. (B) FcεRI-
induced cytokine secretion. Data shown are representative of two 
independent experiments with similar results. (C) Effect of RasGRP1 inac-
tivation on passive systemic anaphylaxis. WT and RasGRP1−/− mice were 
sensitized with anti-DNP IgE. Anaphylaxis was induced by injection with 
DNP-HSA. Histamine concentration in the blood was determined by ELISA 
(n = 5 for both WT and RasGRP1−/− mice). The horizontal bars indicate 
mean values. (D) Normal numbers of mast cells in the peritoneum, back 
skin, and ear dermis.96  RASGRP1 IN FCεRI SIGNALING AND MAST CELL FUNCTION | Liu et al.
by systemic administration of DNP-HSA. At 1.5 min after 
challenge, blood was harvested from these mice. The con-
centration of histamine released into the blood was then 
measured to evaluate IgE-initiated allergic response. A dra-
matic reduction (>95%) in histamine release was observed 
in RasGRP1−/− mice compared with that in WT mice 
(Fig. 2 C).
To assess whether the severe defect in systemic anaphy-
laxis was due to a developmental defect of mast cells in 
  RasGRP1−/− mice, we determined the distribution of mast 
cells in RasGRP1−/− mice. Comparable numbers of mast 
cells were detected in the ear and back skin dermis (Fig. 2 D 
and not depicted) in WT and RasGRP1−/− mice. Similar per-
centages of mast cells were also detected in peritoneal cavities 
using toluidine blue staining and fl   ow cytometry analysis. 
Normal numbers of mast cells in RasGRP1−/− mice indi-
cated that RasGRP1 is not required during mast cell devel-
opment and excluded the possibility that the defective 
anaphylaxis is a consequence of mast cell developmental 
  defects. This conclusion was consistent with our biochemical 
data showing that stem cell factor (SCF) or IL-3–mediated 
Erk and Akt activation was normal in RasGRP1−/− BMMCs 
(not depicted). Therefore, our in vivo and in vitro data 
  suggested that RasGRP1 plays an important role in FcεRI-
initiated mast cell degranulation and systemic anaphylaxis.
Fc𝗆RI-mediated proximal signaling in RasGRP1−/− BMMCs
Our data suggested that defective intracellular signaling might 
be responsible for the impaired degranulation and anaphy-
laxis in the absence of RasGRP1. We next investigated 
whether FcεRI-evoked signaling events are aff  ected  in 
  RasGRP1−/− mast cells. BMMCs were sensitized with anti-
DNP IgE and activated with DNP-HSA for 0, 2, 5, 10, and 
20 min or with PMA for 5 min. Total lysates were prepared 
and analyzed by Western blotting with diff  erent antibodies as 
indicated in Fig. 3. Tyrosine phosphorylation of proteins was 
relatively normal in RasGRP1−/− cells (Fig. 3 A). Because of 
the important role of LAT in organizing the signaling com-
plexes downstream of the FcεRI, we examined phosphoryla-
tion of LAT by blotting with an anti-LATpY191 antibody. 
Normal LAT phosphorylation was detected in RasGRP1−/− 
BMMCs (Fig. 3 A). Tyrosine phosphorylation of PLCγ1 and 
PLCγ2 was also comparable in WT and RasGRP1−/− 
BMMCs (Fig. 3 B). In agreement with normal phosphoryla-
tion of PLCγ1 and PLCγ2, FcεRI-initiated calcium infl  ux 
was intact in RasGRP1−/− BMMCs (Fig. 3 C). These results 
were consistent with previous reports showing that RasGRP1 
functions downstream of PLCγ (13, 14).
MAPK activation in RasGRP1−/− mast cells
RasGRP1 has an established role in TCR-mediated Ras-Erk 
activation. It is also required in PMA (a DAG analogue) 
-  induced Erk activation (14). Because RasGRP1 was expressed 
in mast cells, we next examined whether the Ras-Erk path-
way was aff  ected in the absence of RasGRP1. Surprisingly, 
in contrast with the defective Erk activation in RasGRP1−/− 
thymocytes, FcεRI-mediated Erk activation was normal in 
RasGRP1−/− BMMCs (Fig. 3 D). These data indicated that 
RasGRP1 is not required for Ras-Erk activation in the 
FcεRI signaling pathway. It is possible that other Ras guanyl 
nucleotide exchange factors, such as Sos, or other members 
of the RasGRP family may be the primary activators of this 
pathway. Jnk and p38 were previously shown to be important 
for production of certain cytokines, such as IL-6 (23, 24). 
Figure 3.  Fc𝗆RI-mediated proximal signaling in WT and 
  RasGRP1−/− BMMCs. (A) Tyrosine phosphorylation of proteins after 
FcεRI engagement. After sensitization with anti-DNP IgE, BMMCs were 
stimulated with DNA-HSA or PMA (P) for 5 min. Total lysates were blotted 
with an anti-phosphotyrosine (pY) or anti-LATpY191 antibody. A similar 
amount of lysates loaded in each lane was indicated by an anti-LAT blot. 
(B) Tyrosine phosphorylation of PLCγ1 and PLCγ2. (C) FcεRI-induced cal-
cium infl  ux. Sensitized mast cells were loaded with Indo-1 and stimulated 
with DNP-HSA. The fl  uorescence emission ratio at 405–495 nm was mon-
itored by fl  ow cytometry. (D) Activation of MAPKs. Whole cell lysates were 
analyzed by Western blotting with antibodies against Erk, Jnk, and p38 
and their phosphorylated forms.JEM VOL. 204, January 22, 2007  97
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We also examined Jnk and p38 activation by Western blotting 
with anti–phospho-Jnk and p38. No diff  erences in the activa-
tion of these MAPKs were observed between WT and 
RasGRP1−/− BMMCs (Fig. 3 D). In addition, PMA-induced 
MAPK activation was also normal in the absence of 
RasGRP1 (Fig. 3 D). Collectively, these data suggested that 
RasGRP1 is not required in FcεRI-mediated MAPK activation.
Diminished activation of PI3K pathway
PI3K and its downstream signaling pathway play impor-
tant roles in mast cell function and development (7, 25, 26). 
Genetic inactivation of the p110δ isoform of PI3K leads to 
defective mast cell development and reduced IgE-induced 
degranulation and cytokine release (25). We asked whether 
RasGRP1 could be involved in the activation of the PI3K 
pathway in FcεRI-evoked signaling. To assess the eff  ect of 
RasGRP1 defi  ciency on PI3K activation, we fi  rst assayed the 
PI3K activity by determining production of PIP3 after FcεRI 
stimulation.  32P-labeled mast cells were stimulated with 
DNP-HSA for 0, 2, 5, and 10 min, and lipid fractions were 
extracted and separated by thin layer chromatography. WT 
BMMCs had a threefold increase of PIP3 at 2 min after FcεRI 
stimulation; however, RasGRP1−/− cells only had an in-
crease of 50% (Fig. 4 A). The residual PI3K activity in 
  RasGRP1−/− BMMCs might be due to the compensation of 
RasGRP1 function by other members of the RasGRP 
family. A previous study has shown that the membrane re-
cruitment of PI3K by Gab2 is required for its activation (7). 
We examined Gab2 phosphorylation and its interaction with 
p85. Gab2 was phosphorylated normally and interacted with 
p85 in RasGRP1−/− BMMCs (Fig. 4 B), suggesting that 
RasGRP1 likely controls PI3K activation through a mecha-
nism other than regulating its membrane recruitment by 
Gab2. SHIP acts as a gatekeeper of mast cell degranulation 
through hydrolyzing PIP3 (27). To investigate whether de-
creased PIP3 production in RasGRP1−/− cells was caused by 
increased SHIP activation in RasGRP1−/− mast cells, we ex-
amined SHIP expression and phosphorylation. No substantial 
diff  erences were seen between WT and RasGRP1−/− cells 
(Fig. 4 C).
We next investigated the impact of impaired PI3K activa-
tion on the phosphorylation of molecules in the PI3K path-
way. Akt is recruited to the cell membrane by PIP3 and 
phosphorylated by PDK1 (28). After activation, Akt phos-
phorylates GSK3β and inhibits its activity. Akt and GSK3β 
are critical in FcεRI-induced production of TNFα and IL-2 
by regulating the transcriptional activity of NF-κB, NFAT, 
and AP-1 (29). We examined Akt activation by Western 
blotting with antibodies against Akt phosphorylated at Ser473 
(Fig. 4 D) or Thr308 (Fig. 4 E). FcεRI-mediated Akt phos-
phorylation at these two residues was signifi  cantly reduced in 
RasGRP1−/− BMMCs. The phosphorylation of GSK3β 
(Ser9) was also decreased in RasGRP1−/− BMMCs (Fig. 4 E). 
These results could explain the reduced cytokine produc-
tion in RasGRP1−/− cells. Another molecule downstream of 
PI3K activation is PDK1. Consistent with reduced PIP3 
Figure 4.  Impaired PI3K pathway in RasGRP1−/− BMMCs. (A) Effect 
of RasGRP1 defi  ciency on FcεRI-induced PIP3 production in RasGRP1−/− 
BMMCs. Sensitized cells were labeled with [32P]orthophosphate and stim-
ulated with DNP-HSA. Lipids were then extracted and subjected to thin 
layer chromatography. Increased PIP3 production is plotted in the bottom 
panel. Data shown were from a representative of three independent 
  experiments. (B) Gab2 phosphorylation and its association with p85. Lysates 
were immunoprecipitated with anti-Gab2 followed by Western blotting 
with anti-pY, Gab2, and p85 antibodies. (C) FcεRI-induced SHIP1 (Tyr1020) 
phosphorylation. Whole cell lysates were blotted with anti-pSHIP 
(Tyr1020) and SHIP antibodies. (D and E) Effect of RasGRP1 defi  ciency on 
the PI3K pathway. DNP-HSA or PMA (P) -activated mast cell lysates were 
analyzed by Western blotting with antibodies against phosphorylated AKT 
(Ser473 and Thr308), PDK1 (Ser241), PKCδ (Thr505), and GSK3β (Ser9). 
The numbers shown were normalized relative intensities for the phospho-
rylated Akt, PKD1, and PKCδ, respectively.98  RASGRP1 IN FCεRI SIGNALING AND MAST CELL FUNCTION | Liu et al.
production, phosphorylation of PDK1 was also markedly di-
minished (Fig. 4 D). As a result of the defective PI3K path-
way, phosphorylation of PKCδ, which is mediated by PDK1 
(30), was signifi  cantly diminished (Fig. 4 D). Defective acti-
vation of Akt, PDK1, and PKCδ in RasGRP1−/− cells could 
not be bypassed by stimulation with PMA (Fig. 4 D), sug-
gesting that RasGRP1 is required for signaling downstream 
of DAG production. Collectively, these data indicated that 
activation of molecules in the PI3K pathway is aff  ected by 
RasGRP1 defi  ciency.
N-Ras mediates regulation of PI3K by RasGRP1
To examine whether FcεRI-mediated Ras activation was 
normal, we performed a Ras assay using the GST protein 
fused with the Ras-binding domain (RBD) of Raf (GST-
Raf-RBD). GTP-bound Ras proteins precipitated by GST-
Raf-RBD were detected by Western blotting with antibodies 
against H-Ras, N-Ras, and K-Ras, respectively. As shown in 
Fig. 5 A, the amount of GTP-bound N-Ras precipitated by 
GST-Raf-RBD was reduced in RasGRP1−/− cells, whereas 
the amount of GTP-bound K-Ras was similar in WT and 
RasGRP1−/− cells. GTP-bound H-Ras was not detected 
(not depicted). These data indicated that RasGRP1 is likely 
required for N-Ras activation in FcεRI signaling.
To determine whether the reduced N-Ras activation was 
indeed the cause for defective PI3K activation and degranula-
tion, we introduced the constitutively activated forms (G12V) 
of N-Ras, K-Ras, and H-Ras into RasGRP1−/− BMMCs 
by retroviral transduction. Stable transductants were selected 
and expanded. First, we examined whether PI3K activation 
could be restored by detecting Akt activation. As shown 
in Fig. 5 B, phosphorylation of Akt in RasGRP1−/− cells 
  expressing G12V N-Ras was similar to that in WT cells. 
Expression of G12V K-Ras slightly enhanced Akt phosphor-
ylation in RasGRP1−/− cells, whereas expression of G12V 
H-Ras had no eff  ect. These Ras proteins were expressed at 
comparable amounts as detected by an antibody against the 
HA epitope tag (Fig. 5 B). Next, we assayed whether the de-
fects in FcεRI-mediated degranulation could be corrected by 
expression of constitutively active Ras. We performed the 
β-hexosaminidase release assay with transduced mast cells. 
Although G12V N-Ras rescued the defective degranulation 
in RasGRP1−/− BMMCs, G12V K-Ras or H-Ras had little 
eff  ect (Fig. 5 C). These data indicated that N-Ras is the Ras 
member that is activated by RasGRP1 in mast cells.
Impaired granule translocation in RasGRP1−/− BMMCs
Degranulation is thought to be a two-step process. After 
granules are translocated to the plasma membrane, they are 
fused with the plasma membrane to release their contents 
(10). To visualize the granule release, we introduced a CD63-
GFP fusion protein into BMMCs and monitored granule 
movement under a confocal microscope as described previ-
ously (10). CD63 is mainly localized in the granules of mast 
cells. Before cross-linking with DNP-HSA, mast cell gran-
ules, as revealed by the CD63-GFP fl  uorescence, were mostly 
in the cytosol. After cross-linking, the majority of granules 
moved close to the plasma membrane in WT BMMCs. In 
contrast, granules in RasGRP1−/− cells still remained in the 
cytosol after FcεRI aggregation (Fig. 6 A). After granules are 
fused with the plasma membrane, CD63 can be detected at 
the cell surface (10). We also examined CD63 surface expres-
sion in WT and RasGRP1−/− cells by staining cells with an 
anti-CD63 antibody followed by FACS analysis. We de-
tected an increase of CD63 surface expression on WT cells 
but a very minimal increase on RasGRP1−/− cells (Fig. 6 B). 
Figure 5.  Activation of N-Ras by RasGRP1. (A) Reduced activation of 
N-Ras in RasGRP1−/− BMMCs. Sensitized WT and RasGRP1−/− cells were 
activated with DNP-HSA. Lysates were subjected to GST-Raf-RBD precipi-
tation followed by Western blotting with anti–N-Ras and anti–K-Ras 
antibodies. (B) Reconstitution of Akt activation by constitutively active 
N-Ras. WT and RasGRP1−/− BMMCs transduced with empty vector or 
retroviruses expressing constitutively active forms of N-Ras, K-Ras, and 
H-Ras were sensitized with anti-DNP IgE and cross-linked with DNP-HSA. 
Whole cell lysates were blotted with anti-pAkt, anti-Akt, and anti-HA 
antibodies. (C) Effect of a constitutively active Ras on mast cell degranulation. 
Mast cells were transduced as in B. Mast cell degranulation was assayed 
by measuring the release of β-hexosaminidase.JEM VOL. 204, January 22, 2007  99
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These data indicated that RasGRP1 is critical for granule 
movement in mast cells. Without RasGRP1, mast cells failed 
to move their granules to the plasma membrane to release 
their contents.
Cytoskeleton rearrangement in RasGRP1−/− BMMCs
FcεRI engagement induces cytoskeleton rearrangement that 
includes microtubule formation and disassembly of F-actin 
ring. Granule translocation and degranulation require micro-
tubule formation (10, 12). To investigate why granules failed 
to translocate in RasGRP1−/− BMMCs, we examined 
  formation of microtubule and disassembly of the F-actin 
structures by staining BMMCs with anti–α-tubulin and 
rhodamine-phalloidin, respectively, before and after FcεRI 
  engagement. Cross-linking of sensitized WT mast cells with 
DNP-HSA intensifi  ed network-like staining (green) of tubu-
lin in the cytosol, an indication of the formation of microtu-
bules (Fig. 6 C). In the meantime, F-actin ring, indicated by 
phalloidin staining (red), collapsed after stimulation. In acti-
vated RasGRP1−/− BMMCs, fl  uorescence from anti-tubulin 
staining was only seen near the plasma membrane as in un-
stimulated cells, whereas F-actin disassembly was normal (Fig. 
6 C). These results indicated that RasGRP1-mediated signal-
ing is required for the formation of microtubules after FcεRI 
engagement.
Rac and Rho GTPases can regulate cytoskeletal organi-
zation in eukaryotic cells (31). Recently, RhoA activation 
has been shown to be important for microtubule formation 
and degranulation in mast cells (10). PI3K and its products 
are required for activation of Rho family proteins in several 
pathways (32, 33). We next examined the activation of Rac1 
and RhoA by using GST-PAK-PBD and GST-Rhotekin 
RBD fusion proteins to pull down GTP-bound Rac1 
and RhoA. As shown in Fig. 6 D, activation of Rac1 in 
  RasGRP1−/− cells was similar to that in WT cells. However, 
activation of RhoA was reduced in RasGRP1−/− cells. These 
results suggested that RasGRP1 plays an important role in 
FcεRI-mediated RhoA activation.
DISCUSSION
Disruption of RasGRP1 had no eff  ect on the proximal sig-
naling events after FcεRI engagement. Overall, tyrosine 
phosphorylation of proteins, phosphorylation of LAT and 
PLCγ1/γ2, and calcium infl  ux were intact in RasGRP1−/− 
mast cells. Calcium infl  ux in mast cells is dependent on LAT, 
SLP-76, and PLCγ. LAT or SLP76 defi   ciency causes a 
marked decrease of PLCγ phosphorylation and calcium fl  ux 
(4, 34). RasGRP proteins are activated after binding to DAG, 
a product of PLCγ hydrolysis. Thus, it was not surprising that 
RasGRP1 defi  ciency did not aff  ect FcεRI-mediated proxi-
mal signaling and calcium mobilization. Although PI3K lipid 
products are important for optimal recruitment and activa-
tion of PLCγ1 (35), as well as Tec family kinases (36), their 
importance in FcεRI-mediated calcium mobilization is not 
entirely clear. Mast cells defi  cient in Gab2 or Fyn, two criti-
cal molecules in FcεRI-mediated PI3K activation, only have 
slightly reduced calcium fl  ux. It is possible that in mast cells, 
FcεRI-mediated PLCγ activation and calcium mobilization 
are mainly dependent on recruitment of PLCγ to the plasma 
membrane by LAT. Normal PLCγ phosphorylation and 
Figure 6.  Defective granule translocation, microtubule formation, 
and RhoA activation in RasGRP1−/− BMMCs. (A) FcεRI-induced gran-
ule translocation in WT and RasGRP1−/− BMMCs. BMMCs expressing 
CD63GFP were visualized by confocal microscopy. (B) FcεRI-induced sur-
face CD63 expression analyzed by FACS. (C) FcεRI-induced cytoskeleton 
rearrangement. Sensitized BMMCs were stimulated with DNP-HSA (+) or 
buffer only (−) and stained with anti–α-tubulin (green) and rhodamine-
phalloidin (red). (D) Rac1 and RhoA activation. Whole cell lysates were 
subjected to precipitation by GST-PAK-RBD or GST-Rhotekin-RBD beads, 
respectively. Rac1 and RhoA were detected by Western blotting with an 
anti-Rac1 or anti-RhoA antibody. Lysates were also blotted with these 
antibodies, showing that similar amounts of proteins were used in this 
assay. One representative of three independent experiments was shown.100  RASGRP1 IN FCεRI SIGNALING AND MAST CELL FUNCTION | Liu et al.
calcium mobilization in RasGRP1−/− mast cells suggested 
that DAG production is likely normal in these cells. Defec-
tive PI3K activation and mast cell function were less likely 
due to failed DAG production because PMA-induced activa-
tion of Akt, PKCδ, and PDK1 was still diminished (Fig. 4).
RasGRP1 defi  ciency aff  ects Ras-Erk activation in the 
TCR signaling pathway (14), but not in the FcεRI path-
way based on our data here. Normal activation of Erk in 
RasGRP1−/− mast cells suggested that Sos or other RasGRP 
family members might play a major role in FcεRI-mediated 
Ras-Erk activation. Even though we showed that RasGRP1 
was expressed in BMMCs, its abundance was not as high as 
in T cells. RasGRP4 is a new member of the RasGRP family 
and is highly expressed in mast cells (20, 21). C3H/HeJ mice 
express a unique isoform of RasGRP4 due to an aberrant 
splicing. This aberrant splicing produces a dysfunctional pro-
tein that lacks a DAG-binding domain (C1 domain). These 
mice are hyporesponsive to methacholine stimulation via the 
airway (37), suggesting that RasGRP4 may have an impor-
tant role in mast cell function, although other genes in these 
mice can also contribute to the hyporesponsiveness. We 
speculate that RasGRP4 might play a similar role in mast 
cells as RasGRP1 in T cells in Ras-Erk activation. It is also 
possible that FcεRI-mediated Erk activation might be inde-
pendent of RasGRP proteins. In mast cells, Shc is phosphor-
ylated upon FcεRI engagement (38). Through binding to 
the phosphorylated FcεRI β and γ chains, Shc might recruit 
the Grb2–Sos complex to the plasma membrane to initiate 
Ras-MAPK activation.
Published studies have indicated that PI3K is important in 
mast cell function (1, 3). Gene inactivation or pharmacologi-
cal inhibition of PI3K impairs FcεRI-mediated degranula-
tion and cytokine release (25, 26). Recruitment of the p85 
subunit of PI3K by Gab2 is required for its activation (7). 
However, the mechanism underlying how PI3K is directly 
activated after its localization to membrane has not been 
clearly characterized in mast cells. Our data suggested that full 
activation of PI3K after FcεRI engagement requires not only 
membrane recruitment of p85 by Gab2, but also activation 
by RasGRP1. Our results indicated that RasGRP1 is likely 
involved in PI3K activation through N-Ras. The constitu-
tively active form of N-Ras could rescue defective Akt ac-
tivation and degranulation. GTP-bound Ras has been shown 
to interact with the p110 subunit of PI3K and induce its acti-
vation (8, 39, 40). Effi     cient PI3K activation in platelet-
  derived growth factor–induced signaling requires the function 
of Ras (41). Because RasGRP1 defi   ciency did not aff  ect 
Gab2 phosphorylation and the recruitment of p85, it is likely 
that RasGRP1 activates N-Ras, which further induces PI3K 
activation through its interaction with p110 in FcεRI signal-
ing (Fig. 7). It is not clear why RasGRP1 is only involved in 
the activation of N-Ras, not K-Ras or H-Ras. Despite the 
structural similarities among these Ras proteins, their diff  er-
ential posttranslational modifi  cations target them to diff  erent 
microdomains at the membrane or subcellular compartments 
(42, 43). Recent studies suggest that upon T cell activation, 
RasGRP1 translocates to the Golgi apparatus to activate Ras 
(15). Subsequent studies show that N-Ras is activated upon 
engagement of the TCR and PLCγ1 activation, and RasGRP1 
may activate N-Ras in the Golgi (44). It remains to be deter-
mined whether activation of N-Ras by RasGRP1 in mast 
cells occurs in the Golgi or the plasma membrane.
In contrast with its role in FcεRI-mediated signaling, 
  RasGRP1 is not essential for PI3K and Erk activation in IL-3 
or SCF signaling. IL-3 initiates the Jak-Stat pathway, whereas 
SCF activates the c-Kit receptor tyrosine kinase. Upon phos-
phorylation, the IL-3 receptor and c-Kit bind to the Shc–
Grb2–Sos complex directly to activate the Ras-MAPK pathway 
Figure 7.  A proposed model of RasGRP1 in Fc𝗆RI-mediated signaling. 
Upon FcεRI cross-linking and PIP2 hydrolysis, RasGRP1 is recruited to the 
membrane by DAG to activate N-Ras. N-Ras interacts with the catalytic 
p110 subunit of PI3K, which binds phosphorylated Gab2, and activates 
the PI3K pathway. RasGRP1 also controls RhoA activation indirectly 
through the PI3K pathway.JEM VOL. 204, January 22, 2007  101
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and to p85 to activate the PI3K pathway (45, 46). Why 
  RasGRP1 is required for the FcεRI pathway, but not the 
IL-3– or SCF-mediated pathway, is not clear. It is possible that 
IL-3– or SCF-mediated PI3K activation does not require Ras.
To investigate why RasGRP1−/− cells failed to degranu-
late, we analyzed FcεRI-mediated granule translocation and 
cytoskeletal rearrangement. Our data indicated that granules 
failed to translocate to the plasma membrane, and the forma-
tion of microtubules was defective in RasGRP1−/− cells after 
FcεRI engagement. F-actin rearrangement, which is regu-
lated by Ca2+ and Ca2+-dependent PKCs (10), was normal in 
RasGRP1−/− cells. This result was expected because Ca2+ 
fl  ux was normal in these cells. Our data showed that RhoA 
activation was defective in RasGRP1−/− cells. Vav proteins 
are GEFs for Rho family GTPases (47) and can be regulated 
by the substrates and products of PI3K (32). Diff  erent mem-
bers of the Vav family (Vav1, Vav2, and Vav3) may have dif-
ferent specifi  cities toward diff  erent Rho GTPases, such as 
Cdc42, Rac1, and RhoA (48). It is not clear which GEF spe-
cifi  cally activates Rac1 and RhoA. In RasGRP1−/− cells, 
Rac1 activation was relatively normal, whereas RhoA activa-
tion was reduced. It is possible that RasGRP1 activates the 
PI3K pathway, which in turns activates a specifi  c GEF 
for RhoA, although we cannot exclude the possibility that 
RasGRP1 is also an exchange factor for RhoA in the FcεRI 
signaling pathway.
Lyn and Fyn activate two independent pathways upon en-
gagement of the FcεRI (6). Activation of the Lyn-Syk-LAT 
pathway leads to calcium fl  ux and MAPK activation, whereas 
the Fyn-Gab2-PI3K pathway is responsible for AKT, PKCδ 
activation, and degranulation. It has been proposed that there 
might be cross talks between these two pathways to synergize 
cytokine production and degranulation (6). Our data sug-
gested that RasGRP1 might link LAT phosphorylation and 
PLCγ activation to PI3K activation, thereby connecting the 
Lyn-initiated pathway to the Fyn-initiated pathway in mast 
cells (Fig. 7). In summary, our results indicated that RasGRP1 
is an essential regulator of FcεRI-mediated allergic responses.
MATERIALS AND METHODS
Mice and antibodies. RasGRP1−/− mice were provided by J.C. Stone 
(University of Alberta, Canada). Mice were housed in specifi  c pathogen-free 
conditions, and the use of mice in the experiments described in this study was 
approved by the Duke University Institutional Animal Care Committee.
The following antibodies were used in this study: anti-DNP IgE (SPE-7; 
Sigma-Aldrich), FcεRIα, and c-Kit (eBioscience); PLCγ2, Erk2, K-Ras, 
RhoA, and RasGRP1 (Santa Cruz Biotechnology, Inc.), p85, pTyr (4G10), 
PLCγ1, Rac1, and phospho-LATpY191 (Upstate Biotechnology); and pan-
Ras and N-Ras (Calbiochem). AKT, Jnk, p38, PKCδ, PDK1, and other 
phospho-specifi  c antibodies were from Cell Signaling. Anti-LAT (11B12) 
was described previously (49). Anti-RasGRP4 sera were raised by immunizing 
rabbits with a GST-RasGRP4 fusion protein.
Mast cell culture, stimulation, and degranulation. Bone marrow cells 
were taken from the femurs of WT and RasGRP1−/− mice and were cul-
tured in IMDM supplemented with 10% FBS, β-mercaptoethanol, penicillin, 
and streptomycin in the presence of 5 ng/ml of recombinant IL-3 at 37°C 
for 3–6 wk. For stimulation through the FcεRI, 2 × 106/ml mast cells 
were sensitized with 0.5 μg/ml anti-DNP IgE in IMDM medium without 
IL-3 for 4 h overnight before stimulation with 20 ng/ml DNP-HSA for the 
indicated time points in each fi  gure. For IL-3 or SCF stimulation, cells 
were starved for 24 h in IMDM medium without IL-3 and stimulated with 
20 ng/ml IL-3 or SCF, respectively.
Mast cell degranulation was performed as described previously (49). For 
systemic anaphylaxis, WT and RasGRP1−/− mice were sensitized with anti-
DNP IgE for 24 h and challenged with DNP-HSA for 1.5 min. Blood was 
collected by cardiac puncture, and histamine concentration in the blood was 
determined by ELISA.
Western blotting. Cells were lysed in RIPA buff  er for analysis of whole cell 
lysates or Brij lysis buff  er for immunoprecipitation. For Western blotting, 
  samples were separated by SDS-PAGE and transferred onto nitrocellulose 
membranes. After blocking with 1% fi  sh gelatin, membranes were incubated 
with primary antibodies, washed three times, and probed with either goat 
anti–mouse or anti–rabbit Ig conjugated with Alexa Fluor 680 (Invitrogen) or 
IRDye 800 (Rockland). Membranes were then visualized and quantifi  ed with 
an infrared fl  uorescence imaging system (LI-COR Bioscience Odyssey   system). 
For most of Western blots, samples were resolved on multiple gels and analyzed 
by immunoblotting with diff  erent antibodies.
Numeration of mast cells. Peritoneal fl  ushes were stained with toluidine 
blue. Percentages of mast cells in the peritoneum were calculated as mast cell 
numbers to total cell numbers in fi  ve fi  elds under 200× magnifi  cation. 
Skin sections from the back skin and ear dermis were stained with   toluidine 
blue. Mast cell numbers were counted from at least fi  ve sections from 
each WT (n = 3) and RasGRP1−/− mouse (n = 3). Data are presented as 
mean ± SD.
Calcium infl  ux, cytokine production, and PIP3 measurement. For 
calcium infl  ux, cells were sensitized with 0.5 μg/ml anti-DNP IgE for 4 h 
and loaded with 1.5 μM Indo-1 in 1% FBS-HBSS media for 30 min at 
30°C. Cells were stimulated with 30 ng/ml DNP-HSA to induce calcium 
fl  ux. The fl  uorescence emission ratio at 405–495 nm was monitored by fl  ow 
cytometry. For cytokine production, 2 × 106 anti-DNP IgE sensitized cells 
were stimulated with DNP-HSA for 1 h for RT-PCR and for 8 h for the 
measurement of cytokines released into supernatants using a Bio-Plex cyto-
kine assay (Bio-Rad Laboratories). PIP3 production was determined using 
a protocol described previously (50).
Ras, Rac1, and RhoA activation. For Ras activation, 2 × 107/ml mast 
cells were lysed in a buff  er containing 25 mM Hepes, pH 7.5, 150 mM 
NaCl, 1% NP-40, 0.25% sodium deoxycholate, 10% glycerol, 10 mM 
MgCl2, 1 mM EDTA, and 1 mM Na3VO4. The lysates were incubated with 
20 μg GST-Raf-RBD on glutathione beads for 40 min. Beads were washed 
and boiled in 1× SDS sample buff  er. GST-Rhotekin RBD and GST-PAK-
PBD fusion protein were provided by K. Burridge (University of North 
Carolina, Chapel Hill, NC). Rac1 and RhoA activation was examined by 
pull-down assays as described previously (51). GTP-bound pan-Ras, H-Ras, 
K-Ras, N-Ras, Rac1, and RhoA were detected by Western blotting with 
antibodies against each of these proteins, respectively.
Ras reconstitution by retroviral transduction. Constitutively active forms 
(G12V) of H-Ras, K-Ras, and N-Ras with an HA tag were subcloned into a retro-
viral vector, pMSCV/IRES/Bla. The retroviral plasmids were used to transfect 
Phoenix cells for retrovirus packaging. 12-d-old BMMCs were transduced with 
retroviruses by spin infection. 48 h after transduction, cells were selected with 
5 μg/ml blasticidin and expanded for 10–14 d for subsequent experiments.
Granule translocation and cytoskeletal rearrangement. Examination 
of granule translocation by confocal microscopy was performed as described 
previously (10). In brief, BMMCs were transduced with pMX-CD63GFP 
retroviruses at day 5 after bone marrow culture in IL-3 medium. At 3 wk 
  after the initial culture, BMMCs were sensitized with anti-DNP IgE and 
stimulated with DNP-HSA for 10 min. Cells were immediately fi  xed with 
4% paraformaldehyde before cytospin and visualized by confocal microscopy. 102  RASGRP1 IN FCεRI SIGNALING AND MAST CELL FUNCTION | Liu et al.
For cytoskeletal rearrangement, cells were permeabilized in a buff  er con-
taining 0.1% saponin (2% FBS, 1% BSA, and 0.02% sodium azide in PBS) for 
20 min at room temperature. After cytospin, cells were stained with anti–α-
  tubulin (Sigma-Aldrich) at 1:50 dilution and incubated with Alexa Fluor 488 
goat anti–mouse IgG and rhodamine phalloidin (Invitrogen). Confocal mi-
croscopy was performed using a Zeiss LSM410 confocal system.
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